adjust forecast beigen due aggress price
strategi mnc competitor china lower
btk china asp forecast respect
assum beigen would set price china
around per year nsclc discount
opdivo keytruda lead slightli higher penetr rate
lower peak sale forecast china
lower annual cost per year match
compet drug ibrutinib price recent cut meanwhil
increas compani market share wm base posit
despit increas competit still believ beigen well
posit
strong diversifi pipelin strong
manag team balanc sheet maintain outperform
cut target price also rate compani
outperform dual list
china ibrutinib js btk inhibitor price oncolog drug
price negoti insur depart china overal
sale two drug smaller previou estim
mnc take aggress strategi china much
lower price compar market
cut asp
opdivo keytrud set price china much cheaper
initi expect august result assum beigen
set price china around per year nsclc
around discount opdivo discount keytruda
price pap patient assist program despit cut
estim believ price would still maintain decent
level first player like beigen well posit
market sale manufactur team readi may
necessarili enter price war player
figur price opdivo keytruda china
estimate pot chg tp
 chang prev ep
note note beigen commercial-stag biopharmaceut compani
base china dedic becom global leader discoveri develop
commercialis innov molecularli target immuno-oncolog drug treatment
cancer
click detail financi
figur chang china revenu forecast
new data btk cut asp
lower annual cost per year
match ibrutinib new price china compani releas
posit phase clinic trial data wm waldenstrm
macroglobulinemia see high rate deep durabl respons
across genotyp orr overal respons rate
progression-fre surviv estim
thu adjust market share wm global
market increas oversea revenu forecast
figur china revenu forecast
beigen credit suiss axj focu list stock
chang price assumpt
revis revenu model compani btk
inhibitor cut china price forecast slightli rais
penetr rate revis base mnc price
maintain outperform cut tp
maintain outperform believ beigen lead
posit btk market new tp base
multi-stag dcf model assum wacc perpetu
tp
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
brand nameopdivoindicationnsclc cost pap cost pap charl martineau pm univers toronto
compani mention price
serena shao katherin fu certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
price rate histori beigen bgne oq
signifi initi assumpt coverag
price rate histori bristol-my squibb co bmi
signifi initi assumpt coverag
price rate histori johnson johnson jnj
signifi initi assumpt coverag
price rate histori merck co inc mrk
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst co verag univers
consist compani cover analyst within relev sector outperform repres th attract neutral less attract
underperform least attract invest opportun octob canadian well european ra ting base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri regio nal benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stoc ks expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform wh ere less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap ne utral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cov er multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close correspond
